| | Trials (author, year) | Location | Design | Treatment groups (patients) | Age (y), mean ± SD | Gender M/F | Interventions | Follow-up (month) |
| | Qu et al., 2016 [16] | China | Retrospective subgroup analysis from RCT | 0.5 mg IVC (n = 32)
2.0 mg IVC (n = 21) | 66.5 ± 8.7
63.9 ± 9.6 | 12/20
8/13 | 0.5 mg conbercept 3 + PRN
2.0 mg conbercept 3 + PRN | 3, 12 | | Qi et al., 2019 [17] | China | Prospective | IVC (n = 56) | 68.21 | 31/25 | 0.5 mg conbercept 3 + PRN | 3, 12 | | Cheng et al., 2016 [18] | China | RETRO | type1 PCV (n = 35)
type2 PCV (n = 23) | 66.5 ± 8.7
63.9 ± 9.6 | 22/13 13/10 | 0.5 mg conbercept 3 + PRN | 3, 6, 9, 12 | | Liu et al., 2018 [19] | China | RETRO | IVC (n = 50) | 66.58 ± 4.0 | 34/16 | 0.5 mg conbercept PRN | 3, 6, 12 | | Oishi et al., 2013 [20] | Japan | RCT | IVR (n = 46)
PDT (n = 45) | 75.4 ± 6.9.
75 ± 8.0 | 28/18
32/15 | 0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN | 12, 24 | | Lai et al., 2018 [21] | China | RCT | IVR (n = 18)
PDT (n = 23)
PDT + IVR (n = 16) | 64.67 ± 8.52
60.52 ± 7.77
61.06 ± 9.12 | 12/6
14/9
10/6 | 0.5 mg ranibizumab 1 + PRN
PDT 1 + PRN
IVR + PDT 1 + PRN | 1, 3, 6, 9, 12 | | Marcus et al., 2015 [22] | USA | RCT | 2.0 mgIVR (n = 15)
0.5 mgIVR (n = 5) | 62.6
51.8 | 8/7
3/2 | Ranibizumab 3 + prn | 3, 6, 9, 12 | | Ogino et al., 2013 [23] | Japan | Prospective | IVR (n = 23). | 74.4 ± 6.9 | 18/5 | 0.5 mg ranibizumab 3 + PRN | 3, 12 | | Kokame et al., 2014 [24] | USA | Prospective | IVR (n = 13) | 76.31 | 11/2 | 0.5 mg ranibizumab monthly | 1, 3, 6, 9, 12 | | Hikichi et al., 2014 [25] | Japan | Prospective | IVR (n = 86) | 77 ± 8 | 62/24 | 0.5 mg ranibizumab 3 + PRN | 12 | | Koh et al., 2017 [7] | Japan
Korea
Singapore
Hong Kong
Taiwan
Thailand | RCT | IVR (n = 168)
PDT + IVR (n = 154) | 68.2 ± 9
68.0 ± 8.5 | 116/38
109/59 | 0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN/0.5 mg ranibizumab 3 + PRN | 3, 12 | | Lai et al., 2011 [26] | Hong Kong | RETRO | IVR (n = 7)
IVR + PDT (n = 16)
PDT (n = 12) | 64.6 ± 7.9
71.3 ± 9.8
65.6 ± 11.0 | 4/3
8/8
10/2 | 0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN/0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN | 3, 12 | | Rouvas et al., 2011 [27] | Greece | RETRO | IVR (n = 10)
IVR + PDT (n = 9)
PDT (n = 11) | 66.5
64.67
62.9 | 4/6
4/5
5/6 | 0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN/0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN | 3, 6, 9, 12 | | Inoue et al., 2013 [28] | Japan | RETRO | IVR (n = 33) PDT (n = 44) | 73.2 ± 7.5
71.0 ± 7.8 | 58/42
68/32 | 0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN | 3, 6, 12, 18, 24 | | Sakai et al., 2016 [29] | Japan | RETRO | IVR (n = 20) IVR + PDT (n = 25) | 75.3 ± 8.1
72.6 ± 6.2 | 13/7
21/4 | 0.5 mg ranibizumab 3 + PRN
PDT 1 + PRN/0.5 mg ranibizumab 3 + PRN | 6, 12, 18, 24, 30, 36 | | Cho et al., 2016 [30] | Korea | RETRO | IVA (n = 38)
IVR (n = 60) | 65.37 ± 9.24
63.22 ± 10.44 | 26/12
41/19 | 2 mg aflibercept 3 + PRN
0.5 mg ranibizumab 3 + PRN | 3, 6, 9, 12 | | Takayama et al., 2017 [31] | Japan | RETRO | IVA (n = 11) IVA + PDT (n = 12) | 73.5 ± 4.9
72.9 ± 5.5 | 6/5
6/6 | 0.5 mg aflibercept 3 + PRN
PDT 1 + PRN/0.5 mg aflibercept 3 + PRN | 1, 2, 3, 6, 9, 12 | | Kikushima et al., 2017 [32] | Japan | RETRO | IVA (n = 33)
IVA + PDT (n = 33) | 72.7 ± 8.5
73.4 ± 8.3 | 25/8
22/11 | 2.0 mg aflibercept 3 + PRN
PDT 1 + PRN/2.0 mg aflibercept 3 + PRN | 3, 6, 9, 12 | | Hara et al., 2016 [33] | Japan | RETRO | IVA (n = 29) | 74 ± 8 | 22/6 | 2.0 mg aflibercept 3 + PRN | 1, 2, 3, 6, 12 | | Arakawa et al., 2017 [34] | Japan | Prospective | IVA (n = 22) | 62.5 ± 8.8 | 15/7 | 2.0 mg aflibercept 3 + Q2m | 6, 12 | | Maruyama-Inoue et al., 2018 [35] | Japan | RETRO | IVA 3 + PRN (n = 10)
IVA 3 + Q2m (n = 23) | 67.8 ± 9.3
71.4 ± 7.8 | 6/4
18/5 | 2.0 mg aflibercept 3 + PRN
2.0 mg aflibercept 3 + Q2m | 4, 12, 24, 36 | | Inoue et al., 2016 [36] | Japan | Prospective | IVA 3 + PRN (n = 25)
IVA 3 + Q2m (n = 17) | 71.1 ± 10.6
71.7 ± 7.1 | 13/4
19/6 | 2.0 mg aflibercept 3 + PRN
2.0 mg aflibercept 3 + Q2m | 4, 6, 12 | | Ogasawara et al., 2018 [37] | Japan | RETRO | PCV (n = 64)
AMD (n = 45) | 72.7 ± 7.5
78.0 ± 10.2 | 48/16
37/8 | 2.0 mg aflibercept 3 + Q2m | Every month until month 12 | | Yamamoto et al., 2015 [38] | Japan | RETRO | IVA (n = 90) | 71.1 ± 7.3 | 68/19 | 2.0 mg aflibercept 3 + Q2m | Every month until month 12 | | Yoneda et al., 2019 [39] | Japan | RETRO | IVA (n = 20) IVR + PDT (n = 43) | 69.3 ± 7.5
73.3 ± 7.6 | 15/5
32/11 | 2.0 mg aflibercept 3 + Q2m
PDT 1 + PRN/0.5 mg ranibizumab 3 + PRN | 3, 6, 12, 24 | | Oshima et al., 2017 [40] | Japan | Prospective | IVA (n = 50) | 73.6 ± 7.7 | 36/14 | 2.0 mg aflibercept 3 + Q2m | 6, 12 | | Hosokawa et al., 2017 [41] | Japan | RETRO | IVA (n = 37) | 73.6 (55–89) | 30/7 | 2.0 mg aflibercept
T&E | 3, 6, 9, 12 | | Morimoto et al., 2017 [42] | Japan | RETRO | IVA (n = 58) | 72.4 ± 1.1 | 45/13 | 2.0 mg aflibercept
T&E | 3, 6, 9, 12, 15, 18, 21, 24 | | Lee et al., 2017 [43] | Korea | Prospective | IVA (n = 40) | 67.0 (44–84) | 27/13 | 2.0 mg aflibercept 3 + Q2m | 1, 2, 3, 4, 6, 8, 10, 12 | | Farooq et al., 2017 [44] | USA | Prospective | IVA (n = 20) | 68 (46–90) | 11/9 | 2.0 mg aflibercept 3 + Q2m | 6, 12 |
|
|
